#1 Clinical Trials Search in Europe

Rifapentine

Rifapentine is an antibiotic drug being studied extensively in clinical trials for the treatment and prevention of tuberculosis (TB). These trials aim to evaluate rifapentine’s efficacy, safety, and potential to shorten TB treatment durations compared to standard regimens. Researchers are investigating various doses and combinations of rifapentine with other TB drugs in both adults and children to optimize its use against this widespread infectious disease.

Table of Contents

What is Rifapentine?

Rifapentine is an antibiotic medication used to treat and prevent tuberculosis (TB). It belongs to a class of drugs called rifamycins. Rifapentine is also known by the brand name Priftin[1]. This medication works by killing the bacteria that cause TB.

What is Rifapentine Used For?

Rifapentine is primarily used for:

  • Treating active tuberculosis: Rifapentine is used as part of a combination therapy to treat active TB disease, usually in the lungs[2].
  • Preventing tuberculosis: Rifapentine is also used to prevent TB in people who have been exposed to the bacteria or are at high risk of developing active TB disease. This is known as TB prevention therapy or treatment for latent TB infection[3].

How Does Rifapentine Work?

Rifapentine works by killing the bacteria that cause tuberculosis (Mycobacterium tuberculosis). It does this by interfering with the bacteria’s ability to make RNA, which is essential for the bacteria to survive and multiply. By stopping the bacteria from growing and reproducing, rifapentine helps the body’s immune system to fight off the infection[2].

How is Rifapentine Taken?

Rifapentine is usually taken orally (by mouth) in tablet form. The dosing schedule can vary depending on whether it’s being used to treat active TB or prevent TB. Some common dosing regimens include:

  • For treating active TB: Rifapentine may be taken daily for several months as part of a combination therapy with other TB medications[1].
  • For preventing TB (latent TB treatment):
    • Once-weekly dosing for 12 weeks (3 months), known as the “3HP” regimen[3].
    • Daily dosing for 4 weeks (1 month), known as the “1HP” regimen[4].

The exact dose of rifapentine can vary based on factors like body weight and the specific treatment regimen. It’s important to take rifapentine exactly as prescribed by your healthcare provider.

Potential Side Effects

Like all medications, rifapentine can cause side effects. Common side effects may include:

  • Nausea or vomiting
  • Stomach pain
  • Fever
  • Headache
  • Skin rash
  • Changes in liver function tests

More serious side effects can occur but are less common. These may include severe liver problems or allergic reactions. It’s important to report any unusual symptoms to your healthcare provider[5].

Drug Interactions

Rifapentine can interact with other medications, including some HIV medications. It’s important to tell your healthcare provider about all medications you’re taking, including over-the-counter drugs and supplements. Some key points about drug interactions:

  • Rifapentine may affect the levels of other drugs in your body, potentially making them less effective.
  • If you’re taking HIV medications, especially dolutegravir, your doctor may need to adjust the dosing of these medications when you’re also taking rifapentine[6].
  • Rifapentine can make hormonal birth control methods less effective, so alternative contraception methods may be needed.

Ongoing Research

Researchers are continually studying rifapentine to find the most effective ways to use it for TB treatment and prevention. Some areas of ongoing research include:

  • Testing higher doses of rifapentine to see if they can shorten TB treatment time[7].
  • Studying the use of rifapentine in pregnant women with HIV[4].
  • Investigating rifapentine-based regimens that could reduce TB treatment duration from 6 months to 4 months[1].

These studies aim to improve TB treatment and make it easier for patients to complete their full course of therapy, which is crucial for curing TB and preventing the development of drug-resistant TB strains.

Aspect Details
Main uses of rifapentine in trials Treatment of active TB, prevention of TB in high-risk groups
Potential advantages Shorter treatment duration, possibly improved efficacy at higher doses
Key study designs Dose-escalation studies, pharmacokinetic analyses, comparisons to standard regimens
Patient populations Adults with drug-susceptible pulmonary TB, children, HIV-positive individuals
Combination therapies Studied with isoniazid, pyrazinamide, ethambutol, moxifloxacin
Safety monitoring Adverse events, drug interactions, tolerability of higher doses
Efficacy measures Sputum culture conversion, time to negative culture, relapse rates

FAQ

  • What is rifapentine and how is it used to treat tuberculosis? Rifapentine is an antibiotic drug similar to rifampin that is used to treat and prevent tuberculosis. In clinical trials, it is being studied as a potential replacement for rifampin in TB treatment regimens, with the goal of shortening overall treatment duration from 6 months to 4 months in some cases.
  • What are the potential benefits of using rifapentine instead of standard TB drugs? Potential benefits of rifapentine include shorter treatment durations (4 months instead of 6 months in some regimens), which may improve patient adherence. Some trials are also studying higher doses of rifapentine to see if they provide greater efficacy against TB bacteria.
  • Are there any safety concerns with rifapentine? Clinical trials are closely monitoring the safety and tolerability of rifapentine, especially at higher doses. So far, studies have not shown major safety issues, but researchers continue to evaluate potential side effects and drug interactions, particularly in combination with other TB and HIV medications.
  • Can rifapentine be used to prevent TB in addition to treating active disease? Yes, some clinical trials are studying rifapentine for TB prevention (also called latent TB treatment) in high-risk groups like people with HIV. For example, one study is looking at a 1-month course of daily rifapentine plus isoniazid for TB prevention.
  • Is rifapentine being studied in children with TB? Yes, there are ongoing clinical trials evaluating the use of rifapentine in children, including studies on its pharmacokinetics (how the drug moves through the body) when given with other TB and HIV medications in pediatric patients. This research aims to determine appropriate dosing for children of different ages.

Ongoing Clinical Trials on Rifapentine

  • Study Comparing Rifampicin, Isoniazid, and Rifapentine Regimens for Treating Latent Tuberculosis in Patients with End-Stage Kidney Disease

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Rifapentine: An antibiotic drug similar to rifampin that is used to treat and prevent tuberculosis. It is being studied in clinical trials as a potential replacement for rifampin in some TB treatment regimens.
  • Tuberculosis (TB): An infectious disease caused by bacteria that primarily affects the lungs. It is a major global health problem, especially in developing countries.
  • Latent TB infection: A condition in which a person is infected with TB bacteria but does not have active disease and is not contagious. Treatment can prevent progression to active TB.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion. This helps determine appropriate dosing.
  • Biomarkers: Measurable indicators in the body that can be used to monitor disease progression or treatment response. In TB trials, researchers may look at biomarkers to assess how well drugs are working.
  • Sputum culture conversion: When a person with active TB has a negative sputum culture (no TB bacteria grow from their sputum sample), indicating the treatment is working.
  • Directly observed therapy (DOT): A strategy where a healthcare worker directly observes a patient taking their medication to ensure adherence to the treatment regimen.
  • Drug-susceptible TB: TB that can be treated effectively with standard first-line TB drugs. This is in contrast to drug-resistant TB, which is harder to treat.
  • Intensive phase: The initial period of TB treatment (usually the first 2 months) when more drugs are used to rapidly reduce the number of TB bacteria in the body.
  • Continuation phase: The second, longer period of TB treatment (usually 4 months) that follows the intensive phase and uses fewer drugs to eliminate remaining TB bacteria.

References

  1. https://clinicaltrials.gov/study/NCT02410772
  2. https://clinicaltrials.gov/study/NCT00694629
  3. https://clinicaltrials.gov/study/NCT03900858
  4. https://clinicaltrials.gov/study/NCT05122026
  5. https://clinicaltrials.gov/study/NCT01162486
  6. https://clinicaltrials.gov/study/NCT04551573
  7. https://clinicaltrials.gov/study/NCT00814671